GlobalData on MSN

Satellos’ oral DMD drug improves arm movement after six months in Phase II

In the open-label study, DMD patients received Satellos’ oral drug for an additional 11 months, following an earlier 28-day trial.
MarketBeat on MSN

Satellos Bioscience DMD drug shows early promise in 6-month study update

Key Points Interested in Satellos Bioscience Inc.? Here are five stocks we like better. Satellos Bioscience said its SAT-3247 ...

Satellos Bioscience Duchenne drug candidate's interim data boosts confidence

Recently listed, Satellos Bioscience Inc. MSLE on Wednesday reported six-month interim data from its ongoing TRAILHEAD study ...
SMA News Today

Muscle ultrasound helps assess SMA in children treated with approved drug

Muscle ultrasound helps assess muscle health and its association with motor function in SMA children treated with Spinraza, a ...
BMJ

646 MEP179 – What do upper-extremity physical performance tests measure? Insights from an electromyographical study

Background Upper-extremity physical performance tests (PPTs) are frequently employed for athletic screening because they are easily administered in field settings. Knowledge of muscle activity during ...
Nasdaq

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy

– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity1 – – Pivotal Phase 3 study demonstrated Dysport improved spasticity ...
The American Journal of Managed Care

Assessing Upper-Limb Function in Neuromuscular Diseases: Current Tools and Needs

A review of instruments used to assess upper-limb function in patients with neuromuscular diseases found that more tools are needed to address specific diseases. In most neuromuscular diseases (NMDs), ...